SUB-STUDY 1 CERVICAL CANCER (VOLRUSTOMIG MONOTHERAPY)

Clinical trials for SUB-STUDY 1 CERVICAL CANCER (VOLRUSTOMIG MONOTHERAPY) explained in plain language.

Never miss a new study

Get alerted when new SUB-STUDY 1 CERVICAL CANCER (VOLRUSTOMIG MONOTHERAPY) trials appear

Sign up with your email to follow new studies for SUB-STUDY 1 CERVICAL CANCER (VOLRUSTOMIG MONOTHERAPY), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug combo trial offers hope for Tough-to-Treat cancers

Disease control Recruiting now

This study is testing a new drug called volrustomig, both by itself and combined with chemotherapy, for people with advanced solid tumors that have spread. It is enrolling about 257 adults with specific advanced cancers, including cervical, head and neck, esophageal, and a type o…

Matched conditions: SUB-STUDY 1 CERVICAL CANCER (VOLRUSTOMIG MONOTHERAPY)

Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

SUB-STUDY 1 CERVICAL CANCER (VOLRUSTOMIG MONOTHERAPY)

Get alerted when new SUB-STUDY 1 CERVICAL CANCER (VOLRUSTOMIG MONOTHERAPY) trials appear

New drug combo trial offers hope for Tough-to-Treat cancers